Immunic Target of Unusually Large Options Trading (NASDAQ:IMUX)

Immunic, Inc. (NASDAQ:IMUX) was the recipient of some unusual options trading on Tuesday. Investors acquired 2,229 call options on the company. This represents an increase of 849% compared to the average volume of 235 call options.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Immunic by 70.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock valued at $169,000 after buying an additional 42,383 shares during the period. State Street Corp boosted its holdings in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares during the last quarter. Jane Street Group LLC increased its position in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after purchasing an additional 38,553 shares during the period. Virtu Financial LLC bought a new stake in Immunic during the 3rd quarter worth about $50,000. Finally, HB Wealth Management LLC acquired a new position in Immunic during the 4th quarter valued at about $81,000. Institutional investors own 51.82% of the company’s stock.

Immunic Stock Performance

Shares of NASDAQ IMUX traded up $0.10 during trading on Tuesday, reaching $1.27. The company had a trading volume of 752,365 shares, compared to its average volume of 594,979. Immunic has a 52 week low of $0.92 and a 52 week high of $2.11. The business’s 50 day moving average price is $1.06 and its 200-day moving average price is $1.22. The stock has a market cap of $113.95 million, a PE ratio of -1.03 and a beta of 1.89.

Analysts Set New Price Targets

IMUX has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Immunic in a report on Friday, February 21st. D. Boral Capital restated a “buy” rating and issued a $17.00 price target on shares of Immunic in a research report on Wednesday, February 26th. William Blair started coverage on shares of Immunic in a report on Tuesday. They set an “outperform” rating for the company. Finally, StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $12.67.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.